Biomarker-Driven Lung Cancer

>

Latest News

Neoadjuvant Alectinib Promising for Resectable ALK+ NSCLC
Neoadjuvant Alectinib Promising for Resectable ALK+ NSCLC

June 3rd 2025

The ALNEO trial's final analysis shows neoadjuvant alectinib is effective and well tolerated in resectable stage III ALK-positive NSCLC, achieving 42% MPR and 67% ORR, suggesting a feasible perioperative option.

SACHI Trial: Savolitinib/Osimertinib Improves PFS in MET-Amplified NSCLC
SACHI Trial: Savolitinib/Osimertinib Improves PFS in MET-Amplified NSCLC

June 2nd 2025

Sevabertinib Shows High Response Rates in HER2-Mutant NSCLC
Sevabertinib Shows High Response Rates in HER2-Mutant NSCLC

June 1st 2025

Adagrasib Combo Shows Efficacy in KRAS G12C-Mutant NSCLC
Adagrasib Combo Shows Efficacy in KRAS G12C-Mutant NSCLC

June 1st 2025

FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC
FDA Grants Priority Review to Sevabertinib in HER2-Mutant NSCLC

May 28th 2025

Video Series
Video Interviews

More News